Topic Editors

UNIPRO – Unidade de Investigação em Patologia e Reabilitação Oral, IUCS, CESPU, Rua Central de Gandra, 1317, 4585-116 Gandra PRD, Portugal
Division of Surgical Oncology, Department of Surgery, The Ohio State University, Wexner Medical Center, Columbus, OH 43210, USA

Recent Advances in Anticancer Strategies

Abstract submission deadline
30 April 2024
Manuscript submission deadline
30 June 2024
Viewed by
5605

Topic Information

Dear Colleagues,

The topic "Recent Advances in Anticancer Strategies" aims to provide an overview of the latest developments in the field of cancer treatment. Cancer remains one of the leading causes of death worldwide, and researchers have been working to develop more effective and targeted treatments to improve outcomes for patients. The existing cancer therapies suffer from severe side effects and drug resistance, leading to an increase in cancer incidence and mortality worldwide. Hence, there is a pressing need to develop and discover novel therapeutic strategies that can offer more effective and less toxic treatment options for cancer patients. Novel anticancer approaches are being developed, which can selectively identify and eliminate cancerous cells while minimizing harm to healthy tissues, unlike traditional therapies. For this topic, we welcome original articles and comprehensive reviews that showcase the latest advances in novel anticancer strategies with reduced toxicity and improved therapeutic indices. These articles can suggest potential prospects for optimizing cancer therapies with significant clinical value in the near future. We encourage submissions that focus on the development and validation of various anticancer approaches, including ligand-/receptor-based targeting, controlled drug delivery, gene therapy, gene delivery, immunotherapy, targeted anticancer prodrugs and conjugates (such as photoactivatable caged prodrugs, ADEPT, ADAPT and ADCs), magnetic and ultrasound-mediated drug targeting, and cancer stem cell therapy, as well as strategies that explore the targeting of signaling cascades and the tumor microenvironment. Overall, the topic aims at providing recent advances in anticancer strategies, highlighting the potential impact of these new approaches on cancer treatment and patient outcomes. We eagerly anticipate your valuable contribution to this exciting topic.

Dr. Hassan Bousbaa
Dr. Zhiwei Hu
Topic Editors

Keywords

  • anticancer strategies
  • cancer treatment
  • chemotherapy
  • radiation therapy
  • immunotherapy
  • targeted therapy
  • gene therapy
  • stem cell therapy
  • precision medicine
  • combination therapy
  • biomarkers
  • drug delivery
  • nanoparticles
  • CAR-T cell therapy
  • checkpoint inhibitors
  • epigenetic therapy
  • oncolytic viruses
  • artificial intelligence in cancer treatment

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Biomedicines
biomedicines
4.7 3.7 2013 14.7 Days CHF 2600 Submit
Cancers
cancers
5.2 7.4 2009 18.2 Days CHF 2900 Submit
Future Pharmacology
futurepharmacol
- - 2021 19.4 Days CHF 1000 Submit
Pharmaceutics
pharmaceutics
5.4 6.9 2009 17 Days CHF 2900 Submit

Preprints is a platform dedicated to making early versions of research outputs permanently available and citable. MDPI journals allow posting on preprint servers such as Preprints.org prior to publication. For more details about reprints, please visit https://www.preprints.org.

Published Papers (4 papers)

Order results
Result details
Journals
Select all
Export citation of selected articles as:
29 pages, 2646 KiB  
Review
Targeting Glucose Metabolism in Cancer Cells as an Approach to Overcoming Drug Resistance
Pharmaceutics 2023, 15(11), 2610; https://doi.org/10.3390/pharmaceutics15112610 - 10 Nov 2023
Viewed by 1057
Abstract
The “Warburg effect” consists of a metabolic shift in energy production from oxidative phosphorylation to glycolysis. The continuous activation of glycolysis in cancer cells causes rapid energy production and an increase in lactate, leading to the acidification of the tumour microenvironment, chemo- and [...] Read more.
The “Warburg effect” consists of a metabolic shift in energy production from oxidative phosphorylation to glycolysis. The continuous activation of glycolysis in cancer cells causes rapid energy production and an increase in lactate, leading to the acidification of the tumour microenvironment, chemo- and radioresistance, as well as poor patient survival. Nevertheless, the mitochondrial metabolism can be also involved in aggressive cancer characteristics. The metabolic differences between cancer and normal tissues can be considered the Achilles heel of cancer, offering a strategy for new therapies. One of the main causes of treatment resistance consists of the increased expression of efflux pumps, and multidrug resistance (MDR) proteins, which are able to export chemotherapeutics out of the cell. Cells expressing MDR proteins require ATP to mediate the efflux of their drug substrates. Thus, inhibition of the main energy-producing pathways in cancer cells, not only induces cancer cell death per se, but also overcomes multidrug resistance. Given that most anticancer drugs do not have the ability to distinguish normal cells from cancer cells, a number of drug delivery systems have been developed. These nanodrug delivery systems provide flexible and effective methods to overcome MDR by facilitating cellular uptake, increasing drug accumulation, reducing drug efflux, improving targeted drug delivery, co-administering synergistic agents, and increasing the half-life of drugs in circulation. Full article
(This article belongs to the Topic Recent Advances in Anticancer Strategies)
Show Figures

Graphical abstract

20 pages, 2401 KiB  
Review
The Value of Microbes in Cancer Neoantigen Immunotherapy
Pharmaceutics 2023, 15(8), 2138; https://doi.org/10.3390/pharmaceutics15082138 - 14 Aug 2023
Viewed by 853
Abstract
Tumor neoantigens are widely used in cancer immunotherapy, and a growing body of research suggests that microbes play an important role in these neoantigen-based immunotherapeutic processes. The human body and its surrounding environment are filled with a large number of microbes that are [...] Read more.
Tumor neoantigens are widely used in cancer immunotherapy, and a growing body of research suggests that microbes play an important role in these neoantigen-based immunotherapeutic processes. The human body and its surrounding environment are filled with a large number of microbes that are in long-term interaction with the organism. The microbiota can modulate our immune system, help activate neoantigen-reactive T cells, and play a great role in the process of targeting tumor neoantigens for therapy. Recent studies have revealed the interconnection between microbes and neoantigens, which can cross-react with each other through molecular mimicry, providing theoretical guidance for more relevant studies. The current applications of microbes in immunotherapy against tumor neoantigens are mainly focused on cancer vaccine development and immunotherapy with immune checkpoint inhibitors. This article summarizes the related fields and suggests the importance of microbes in immunotherapy against neoantigens. Full article
(This article belongs to the Topic Recent Advances in Anticancer Strategies)
Show Figures

Figure 1

44 pages, 2410 KiB  
Review
The Neurodevelopmental and Molecular Landscape of Medulloblastoma Subgroups: Current Targets and the Potential for Combined Therapies
Cancers 2023, 15(15), 3889; https://doi.org/10.3390/cancers15153889 - 30 Jul 2023
Viewed by 1395
Abstract
Medulloblastoma is the most common malignant pediatric brain tumor and is associated with significant morbidity and mortality in the pediatric population. Despite the use of multiple therapeutic approaches consisting of surgical resection, craniospinal irradiation, and multiagent chemotherapy, the prognosis of many patients with [...] Read more.
Medulloblastoma is the most common malignant pediatric brain tumor and is associated with significant morbidity and mortality in the pediatric population. Despite the use of multiple therapeutic approaches consisting of surgical resection, craniospinal irradiation, and multiagent chemotherapy, the prognosis of many patients with medulloblastoma remains dismal. Additionally, the high doses of radiation and the chemotherapeutic agents used are associated with significant short- and long-term complications and adverse effects, most notably neurocognitive delay. Hence, there is an urgent need for the development and clinical integration of targeted treatment regimens with greater efficacy and superior safety profiles. Since the adoption of the molecular-based classification of medulloblastoma into wingless (WNT) activated, sonic hedgehog (SHH) activated, group 3, and group 4, research efforts have been directed towards unraveling the genetic, epigenetic, transcriptomic, and proteomic profiles of each subtype. This review aims to delineate the progress that has been made in characterizing the neurodevelopmental and molecular features of each medulloblastoma subtype. It further delves into the implications that these characteristics have on the development of subgroup-specific targeted therapeutic agents. Furthermore, it highlights potential future avenues for combining multiple agents or strategies in order to obtain augmented effects and evade the development of treatment resistance in tumors. Full article
(This article belongs to the Topic Recent Advances in Anticancer Strategies)
Show Figures

Figure 1

16 pages, 1760 KiB  
Review
FLASH Radiotherapy and the Use of Radiation Dosimeters
Cancers 2023, 15(15), 3883; https://doi.org/10.3390/cancers15153883 - 30 Jul 2023
Cited by 1 | Viewed by 1173
Abstract
Radiotherapy (RT) using ultra-high dose rate (UHDR) radiation, known as FLASH RT, has shown promising results in reducing normal tissue toxicity while maintaining tumor control. However, implementing FLASH RT in clinical settings presents technical challenges, including limited depth penetration and complex treatment planning. [...] Read more.
Radiotherapy (RT) using ultra-high dose rate (UHDR) radiation, known as FLASH RT, has shown promising results in reducing normal tissue toxicity while maintaining tumor control. However, implementing FLASH RT in clinical settings presents technical challenges, including limited depth penetration and complex treatment planning. Monte Carlo (MC) simulation is a valuable tool for dose calculation in RT and has been investigated for optimizing FLASH RT. Various MC codes, such as EGSnrc, DOSXYZnrc, and Geant4, have been used to simulate dose distributions and optimize treatment plans. Accurate dosimetry is essential for FLASH RT, and radiation detectors play a crucial role in measuring dose delivery. Solid-state detectors, including diamond detectors such as microDiamond, have demonstrated linear responses and good agreement with reference detectors in UHDR and ultra-high dose per pulse (UHDPP) ranges. Ionization chambers are commonly used for dose measurement, and advancements have been made to address their response nonlinearities at UHDPP. Studies have proposed new calculation methods and empirical models for ion recombination in ionization chambers to improve their accuracy in FLASH RT. Additionally, strip-segmented ionization chamber arrays have shown potential for the experimental measurement of dose rate distribution in proton pencil beam scanning. Radiochromic films, such as GafchromicTM EBT3, have been used for absolute dose measurement and to validate MC simulation results in high-energy X-rays, triggering the FLASH effect. These films have been utilized to characterize ionization chambers and measure off-axis and depth dose distributions in FLASH RT. In conclusion, MC simulation provides accurate dose calculation and optimization for FLASH RT, while radiation detectors, including diamond detectors, ionization chambers, and radiochromic films, offer valuable tools for dosimetry in UHDR environments. Further research is needed to refine treatment planning techniques and improve detector performance to facilitate the widespread implementation of FLASH RT, potentially revolutionizing cancer treatment. Full article
(This article belongs to the Topic Recent Advances in Anticancer Strategies)
Show Figures

Figure 1

Back to TopTop